Journal
PHARMACEUTICS
Volume 13, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics13040504
Keywords
inhalation; pulmonary drug delivery; caspofungin; antifungal; formulation; peptide(s); chemical stability; solid-state stability; pharmacokinetic; pharmacodynamic (PK; PD) correlation
Categories
Funding
- Trilogy Therapeutics, Inc.
Ask authors/readers for more resources
By reformulating caspofungin for aerosolization, high drug concentration in the lungs is achieved with minimal systemic distribution, leading to significant increase in lung deposition and potential improvement in efficacy, supporting the need for further animal toxicology studies and human clinical trials for treating IPA with inhaled caspofungin.
Invasive Pulmonary Aspergillosis (IPA) and Pneumocystis jiroveci Pneumonia (PCP) are serious fungal pulmonary diseases for immunocompromised patients. The brand name drug CANCIDAS(R) (Caspofungin acetate for injection) is FDA approved to treat IPA, but is only 40% effective. Efficacious drug levels at the lung infection site are not achieved by systemic administration. Increasing the dose leads to toxicity. The objective, here, is to reformulate caspofungin for aerosolization to high drug concentration by lung targeted delivery and avoid systemic distribution. Described in this paper is a new, room temperature-stable formulation that meets these goals. The in vitro antifungal activity, solid state and reconstituted stability, and aerosol properties of the new formulation are presented. In addition, pharmacokinetic parameters and tissue distribution data are determined from nose-only inhalation studies in rats. Plasma and tissue samples were analyzed by High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS-MS). Inhaled drug concentrations for caspofungin Active Pharmaceutical Ingredient (API), and the new formulation, were compared at the same dose. In the lungs, the parameters C-max and Area Under Curve (AUC) showed a 70%, and 60%, respective increase in drug deposition for the new formulation without significant systemic distribution. Moreover, the calculated pharmacodynamic indices suggest an improvement in efficacy. These findings warrant further animal toxicology studies and human clinical trials, with inhaled caspofungin, for treating IPA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available